MacroGenics Inc. Announces Clinical Update on Phase 1 MGC026

What Happened MacroGenics, Inc. (MGNX) announced a clinical update for its ongoing Phase 1 study of MGC026 in a press release dated July 23, 2026. The company filed a Form 8-K (Item 8.01) to report the event and attached the press release as Exhibit 99.1 to the filing. The report was signed on behalf of MacroGenics by Jeffrey Peters, Senior Vice President, General Counsel and Corporate Secretary.

Key Details

• Event: Clinical update on the Phase 1 study of MGC026.
• Filing date and press release: July 23, 2026; press release is Exhibit 99.1 to the Form 8-K.
• SEC item: Reported under Item 8.01 (Other Events); no financial statements or corporate officer changes disclosed in this filing.
• Authorized signature: Jeffrey Peters, SVP, General Counsel & Corporate Secretary.

Why It Matters Clinical updates can affect a biotechnology company’s development timeline and investor expectations about a drug candidate’s progress. This 8-K formally notifies investors that MacroGenics has released new information about MGC026; investors should read the attached press release (Exhibit 99.1) for specifics on safety, efficacy, enrollment, or next steps. This filing itself does not include financial results or other corporate actions.